Skip to main content

Funding of REMEDY

The research center REMEDY is financed with 128 million through the scheme Research center for clinical treatment (FKB) from the Research Council over a period of 8 years. The center has also received an award from the Olav Thon Foundation of 32 million over the same time period.

The Research Council

Research centers for clinical treatment (FKB) are funded by the Research Council and will contribute to improving the treatment of Norwegian patients through outstanding research. The primary research tasks of the center are to carry out clinical studies. The centers will also contribute to the transfer of basic discoveries to clinical application, increase national and international collaboration, and train competent clinicians and clinical researchers. The centers have the option of support from the Research Council for up to eight years (5 + 3 years). The allocation is a maximum of 160 million. In addition to this, the research center provides its own funding that corresponds to the awards received.

The Olav Thon Foundation

The Olav Thon Foundation was established in 2013, and a main purpose is to support non-profit causes. The foundation's articles of association were amended at the end of 2021, so that the annual payment is increased from NOK 50 million to NOK 100 million. Half of this frame will now be earmarked for musculoskeletal purposes, as part of founder Olav Thon's long-term commitment to the societal consequences of musculoskeletal diseases.